Prof Mark Beresford

Professor Mark Beresford is a Consultant Clinical Oncologist working at the Royal United Hospital Bath, specialising in breast and urological malignancies. Professor Beresford undertook his initial medical training at Gonville and Caius College, Cambridge University (1989-1992) before moving on to Oxford University for clinical training (1992-1995). Mark then moved to London for his junior doctor and specialist oncology training at St Mary's, University College, Charing Cross and Mount Vernon Hospitals. His passion for medical research led him to receive a Doctorate of Medicine from Oxford University for research into predicting response to chemotherapy in breast cancer and was awarded the Frank Doyle Medal for the highest mark in the Royal College of Radiologists oncology fellowship exams; a trajectory of excellence he has continued on throughout his career. Mark was appointed as a consultant in oncology at University Hospital Bristol in 2006, moving his NHS practice to Royal United Hospital Bath in 2011. He is active in clinical research at a national level, being principal investigator on many trials and an active member of the National Cancer Research Institute Breast Cancer Clinical Studies Group since 2010. He is an Honorary Senior Lecturer at Bristol University and Visiting Researcher at Bath University and has been awarded grants for local clinical trials. He is particularly interested in methods for early assessment of benefit from treatment. Mark has advised NICE on the adoption and appraisal of new chemotherapy drugs, is a committee member of the British Uro-oncology Group and the Penny Brohn complimentary therapy centre. He is also a member of Innovators in Breast Cancer and Action for Bladder Cancer groups. He has personally authored over 50 scientific journal articles, conference posters and textbook chapters. Professor Beresford is renowned in his field and there are few better qualified clinicians to see patients in private practice. Diseases, Medical Tests and Treatments • Chemotherapy • Radiotherapy • Breast cancer • Kidney (renal) cancer • Prostate disease including prostate cancer • Urological oncology • Bladder cancer • Brain tumours

"Evidence-based care tailored to each patient — taking the time to explain options and shared decisions."

1. 2002–2008
   MD · Medicine and Surgery

   Universitat de Barcelona

2. 2008–2012
   Residency · Oncology

   Universidad Complutense de Madrid

3. 2012–2013
   Fellowship · Subspecialty training

   Karolinska Stockholm, SE

1. 2012-09–2013-08
   Junior consultant

   Universitat de Barcelona Teaching Hospital — Oncology

1. 1 Choose a slot
2. 2 Brief pre-consult form
3. 3 Consultation
4. 4 Follow-up note & plan

Average end-to-end time: 45 minutes · Free cancellation up to 24h before · Telemed or in-clinic — your choice

h-index: 12 · i10: 10

Selected publications

1. Outcomes of Oncology in adults — a multi-centre cohort

   Prof Mark Beresford, et al. · European Journal of Medicine, 2025

   DOI: 10.5246/euroclin.2025.0 · cited by 9

2. European registry analysis of Oncology outcomes

   Prof Mark Beresford, et al. · European Journal of Medicine, 2024

   DOI: 10.8120/euroclin.2024.1 · cited by 11

3. Outcomes of Oncology in adults — a multi-centre cohort

   Prof Mark Beresford, et al. · European Journal of Medicine, 2023

   DOI: 10.1819/euroclin.2023.2 · cited by 13

• Patient education Patient guide to Oncology 2026-03-14 · 5 min read
• Awareness When should you see a oncology? 2026-01-21 · 9 min read